Arcturus Therapeutics Holdings Inc (ARCT)

01:50 AM

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $66.75 Consensus Target Price from Analysts - Defense World

01:50 AM

Jan 21, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Significant Increase in Short Interest - Defense World

Jan 21, 2025

Jan 19, 2025

Hennion & Walsh Asset Management Inc. Acquires 47,824 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat

Jan 19, 2025

Jan 15, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Earns Buy Rating from HC Wainwright - Defense World

Jan 15, 2025

Jan 13, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Receives Buy Rating from HC Wainwright - MarketBeat

Jan 13, 2025

Jan 10, 2025

Arcturus Therapeutics launches Phase I Avian Influenza trials in US - Yahoo Finance

Jan 10, 2025

Jan 10, 2025

Arcturus Launches Phase 1 Trial for Next-Gen H5N1 Flu Vaccine with BARDA Funding - StockTitan

Jan 10, 2025

Jan 09, 2025

Arcturus Therapeutics Holdings Inc (ARCT) Recovers 32.52% From Low: Are We There Yet? - Stocks Register

Jan 09, 2025

Jan 09, 2025

HC Wainwright Reiterates Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT) - Defense World

Jan 09, 2025

Jan 08, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 8.6%Should You Sell? - MarketBeat

Jan 08, 2025

Jan 08, 2025

Arcturus Therapeutics' SWOT analysis: sa-mRNA stock poised for growth amid challenges - Investing.com India

Jan 08, 2025

Jan 07, 2025

Arcturus up 9% as phase 2 dosing begins for mRNA asset for cystic fibrosis - MSN

Jan 07, 2025

Jan 07, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Trading 5.9% HigherWhat's Next? - MarketBeat

Jan 07, 2025

Jan 07, 2025

Arcturus Therapeutics' (ARCT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Jan 07, 2025

Jan 06, 2025

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency - Business Wire

Jan 06, 2025

Dec 31, 2024

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Acquired by Geode Capital Management LLC - Defense World

Dec 31, 2024

Dec 28, 2024

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $66.75 Consensus Price Target from Analysts - Defense World

Dec 28, 2024

Dec 27, 2024

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Holdings Increased by Franklin Resources Inc. - Defense World

Dec 27, 2024

Dec 27, 2024

Franklin Resources Inc. Acquires 36,714 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat

Dec 27, 2024

Dec 26, 2024

Head-To-Head Survey: Zymeworks (NYSE:ZYME) versus Arcturus Therapeutics (NASDAQ:ARCT) - Defense World

Dec 26, 2024

Dec 24, 2024

High Growth Tech Stocks Including Arcturus Therapeutics Holdings And Two Others - Simply Wall St

Dec 24, 2024

Dec 21, 2024

State Street Corp Sells 50,883 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat

Dec 21, 2024

Dec 20, 2024

We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate - Yahoo Finance

Dec 20, 2024

Dec 19, 2024

Arcturus Therapeutics stock hits 52-week low at $14.82 - Investing.com India

Dec 19, 2024

Dec 19, 2024

Wellington Management Group LLP Lowers Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat

Dec 19, 2024

Dec 19, 2024

HC Wainwright Reiterates “Buy” Rating for Arcturus Therapeutics (NASDAQ:ARCT) - Defense World

Dec 19, 2024

Dec 18, 2024

Arcturus Therapeutics stock hits 52-week low at $14.82 By Investing.com - Investing.com Canada

Dec 18, 2024

Dec 17, 2024

Arcturus Therapeutics (NASDAQ:ARCT) Given “Overweight” Rating at Cantor Fitzgerald - Defense World

Dec 17, 2024

Dec 16, 2024

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - StockTitan

Dec 16, 2024

Dec 16, 2024

Arcturus Therapeutics' SWOT analysis: mRNA vaccine stock faces pivotal year - Investing.com

Dec 16, 2024

Dec 16, 2024

Cantor Fitzgerald Reaffirms "Overweight" Rating for Arcturus Therapeutics (NASDAQ:ARCT) - MarketBeat

Dec 16, 2024

Dec 15, 2024

BNP Paribas Financial Markets Raises Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Dec 15, 2024

Dec 14, 2024

Arcturus Therapeutics Holdings (NASDAQ:ARCT shareholders incur further losses as stock declines 9.8% this week, taking three-year losses to 63% - Simply Wall St

Dec 14, 2024

Dec 12, 2024

Fmr LLC Sells 112,516 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat

Dec 12, 2024

Dec 11, 2024

Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers - Yahoo Finance

Dec 11, 2024

Dec 10, 2024

10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey

Dec 10, 2024

Dec 08, 2024

mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider - GlobeNewswire Inc.

Dec 08, 2024

Dec 07, 2024

Arcturus Therapeutics (NASDAQ:ARCT) Shares Up 13.3%Here's Why - MarketBeat

Dec 07, 2024

Dec 07, 2024

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma - The Eastern Progress Online

Dec 07, 2024

Dec 05, 2024

Arcturus Therapeutics' SWOT analysis: vaccine maker's stock faces challenges, opportunities - Investing.com Nigeria

Dec 05, 2024

Dec 05, 2024

Portolan Capital Management LLC Sells 355,763 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat

Dec 05, 2024